Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

Abstract: A garment for regulating temperature is provided, with a body including a back panel and at least one front panel and at least partially joined along at least one common edge, an inner liner panel fastened to an inner surface of at least one of the back panel and to the at least one front panel with a first surface, and a second surface opposite to the first surface of the inner liner panel, and at least one pocket with top, bottom and side edges, being fastened to at least one of the first and second surfaces of the inner removable liner panel. The at least one pocket has at least one side opening.

Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

Abstract: A garment for regulating temperature is provided, with a body including a back panel and at least one front panel and at least partially joined along at least one common edge, an inner liner panel fastened to an inner surface of at least one of the back panel and to the at least one front panel with a first surface, and a second surface opposite to the first surface of the inner liner panel, and at least one pocket with top, bottom and side edges, being fastened to at least one of the first and second surfaces of the inner removable liner panel. The at least one pocket has at least one side opening.

Abstract: A garment for regulating temperature is provided, with a body including a back panel and at least one front panel and at least partially joined along at least one common edge, an inner liner panel fastened to an inner surface of at least one of the back panel and to the at least one front panel with a first surface, and a second surface opposite to the first surface of the inner liner panel, and at least one pocket with top, bottom and side edges, being fastened to at least one of the first and second surfaces of the inner removable liner panel. The at least one pocket has at least one side opening.

Abstract: A garment for regulating temperature is provided, including a body having a back panel and at least one front panel made of a temperature insulating textile and partially joined along at least one common edge, the joined panels defining an inside chamber. At least one pocket having a top, bottom and side edges, is fastened to an inner surface of at least one of the front panel and the back panel on at least one side of the at least one pocket. The at least one pocket has at least one side opening.

Abstract: A garment for regulating temperature includes a body having a back panel and at least one front panel made of a temperature insulating textile and partially joined along at least one common edge, the joined panels defining an inside chamber. At least one pocket is fastened to an inside surface of at least one of the front panel and the back panel. The at least one pocket is configured for accommodating a temperature regulating element.

Abstract: A garment for regulating temperature includes a body having a back panel and at least one front panel made of a temperature insulating textile and partially joined along at least one common edge, the joined panels defining an inside chamber. At least one pocket is fastened to an inside surface of at least one of the front panel and the back panel. The at least one pocket is configured for accommodating a temperature regulating element.

Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

Abstract: A garment for regulating temperature includes a body having a back panel and at least one front panel made of a temperature insulating textile and partially joined along at least one common edge, the joined panels defining an inside chamber. At least one pocket is fastened to an inside surface of at least one of the front panel and the back panel. The at least one pocket is configured for accommodating a temperature regulating element.

Abstract: Publishing to a publicly-accessible wide area network an availability file containing information on an individual's availability to attend a proposed meeting. A user input, indicating the occurrence of an event, is accepted. Availability information is parsed out of the user input and published to an availability file located on a file server connected to a publicly accessible wide area network. The availability file is maintained in a commonly-recognized file format. Others can access the availability file over the publicly-accessible wide area network to ascertain the user's availability to participate in a proposed event, such as attendance of a proposed meeting. These parties, however, do not have access to the user's details of the occurrence of the event.

Abstract: An implant for use in bone augmentation includes a hollow casing made of a resorbable material and a prosthetic filling material for bones contained within the casing. A method for bone augmentation includes the steps of making an incision adjacent to the augmentation site, inserting an implant comprising a hollow casing made of resorbable porous material and filled with a prosthetic filling material for bones, into the augmentation site directed via the incision, and closing the incision.